V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Pliant Therapeutics Executive Compensation (FY25)

PLRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Bernard Coulie
Latest say-on-pay support
=
June 11, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Pliant Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 11, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Pliant Therapeutics brief$1,500Get the executive brief
Velarion Member, one year
231 figures on this page: 226 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Bernard Coulie: $6,614,704 → $5,462,901 (17.4% lower)
Say-on-pay support: 77.1% → 51.2% (25.9 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Pliant Therapeutics' chief executive and what were they paid?
Total compensation for Bernard Coulie, President, Chief Executive Officer and Director, came to $5,462,901 in fiscal 2025. Coulie's total was 17.4% lower than the $6,614,704 reported for fiscal 2024.
What was Pliant Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 51.2% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in Pliant Therapeutics' peer group?
The disclosed peer group names 4D Molecular Therapeutics, Akero Therapeutics, Alector, Arcturus Therapeutics and Crinetics Pharmaceuticals, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Coulie
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Éric Lefebvre
Chief Medical Officer
◇—◇◇◇—◇◇
Keith Cummings
Chief Financial Officer
◇—◇◇◇—◇◇
Hans Hull
Chief Business Officer
◇—◇◇◇—◇◇
Mike Ouimette
General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Coulie
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Éric Lefebvre
Chief Medical Officer
◇—◇◇◇—◇◇
Keith Cummings
Chief Financial Officer
◇—◇◇◇—◇◇
Hans Hull
Chief Business Officer
◇—◇◇◇—◇◇
Mike Ouimette
Chief Legal and Compliance Officer and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Coulie
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Keith Cummings
Chief Financial Officer
◇—◇◇◇—◇◇
Éric Lefebvre
Chief Medical Officer
◇—◇◇◇—◇◇
Hans Hull
Chief Business Officer
◇—◇◇◇—◇◇
Mike Ouimette
Chief Legal and Compliance Officer and Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Bernard Coulie
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Eric Lefebvre
Former Chief Medical Officer
Departed during or after this year
◇◇◇◇——◇◇
Keith Cummings
Chief Financial Officer
◇◇◇◇◇—◇◇
Minnie Kuo
Chief Operating Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bernard CoulieOTHER——————◇
Eric LefebvreOTHER——————◇
Keith CummingsOTHER——————◇
Minnie KuoOTHER——————◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric LefebvreOption◇—◇1/23/2035
RSU◇◇——
Option◇—◇1/25/2033
Option◇—◇1/23/2034
RSU◇◇——
RSU◇◇——
Option◇—◇1/26/2032
Bernard CoulieOption◇—◇1/23/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/26/2032
Option◇—◇1/25/2033
Option◇—◇—
Keith CummingsRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/26/2032
Option◇—◇1/25/2033
Option◇—◇1/23/2034
Option◇—◇1/23/2035
Minnie KuoRSU◇◇——
RSU◇◇——
Option◇—◇9/14/2033
Option◇—◇1/23/2034
Option◇—◇1/23/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Hoyoung Huh
◇—◇———◇
Steve Krognes
◇—◇———◇
Katharine Knobil
◇—◇———◇
Gayle Crowell
◇—◇———◇
Darren Cline
◇—◇———◇
David Pyott
◇—◇———◇
Thomas McCourt
◇—◇———◇
Suzanne Bruhn
◇—◇———◇
John Curnutte
◇—◇———◇
Smital Shah
◇—————◇
Bernard Coulie served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 4D Molecular Therapeutics FDMT
  • Akero Therapeutics AKRO
  • Alector ALEC
  • Arcturus Therapeutics ARCT
  • Crinetics Pharmaceuticals CRNX
  • Day One Biopharmaceuticals DAWN
  • Disc Medicine IRON
  • Erasca ERAS
  • IDEAYA Biosciences IDYA
  • IGM Biosciences IGMS
  • iTeos Therapeutics ITOS
  • KalVista Pharmaceuticals KALV
  • Keros Therapeutics KROS
  • Kura Oncology KURA
  • Kymera Therapeutics KYMR
  • Olema Pharmaceuticals OLMA
  • Protagonist Therapeutics PTGX
  • Replimune Group REPL
  • Rocket Pharmaceuticals RCKT
  • Scholar Rock SRRK
  • Structure Therapeutics, Inc. GPCR
  • Viridian Therapeutics VRDN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 5, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 7, 2023=◇◇◇
2021June 16, 2022=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Bernard Coulie (President, Chief Executive Officer and Director), FY2025 total compensation $5,462,901 (base salary $682,000) [exec_comp, SEC accession 0001746473-26-000076, filed 2026-04-22]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Pliant Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Pliant Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pliant Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Pliant Therapeutics recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Pliant Therapeutics' disclosed peer group is defensible, who names Pliant Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
231 figures on this page: 226 cited to the filing that reported them, 5 calculated from figures it prints.
226 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001746473-26-000092
  2. 0001746473-26-000076
    Director Compensation · TABLE OF CONTENTS EXECUTIVE COMPENSATION
  3. 0001746473-25-000105
  4. 0001746473-25-000089
  5. 0001746473-24-000084
  6. 0001746473-23-000036
  7. 0001193125-22-176473
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pliant Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PLRX (accessed 2026).
Short form: data: Velarion

The Pliant Therapeutics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pliant Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Pliant Therapeutics discloses

The companies named in PLRX's own disclosed peer group.

4D Molecular TherapeuticsAkero TherapeuticsAlectorArcturus TherapeuticsCrinetics PharmaceuticalsDay One BiopharmaceuticalsDisc MedicineErascaIDEAYA BiosciencesIGM BiosciencesiTeos TherapeuticsKalVista PharmaceuticalsKeros TherapeuticsKura OncologyKymera TherapeuticsOlema PharmaceuticalsProtagonist TherapeuticsReplimune GroupRocket PharmaceuticalsScholar RockStructure Therapeutics, Inc.Viridian Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy